Patient Volume Help Offset Impact Of Discounting For Gilead’s HCV Franchise
Executive Summary
New patient starts on hepatitis C therapy are well above projections, enabling Gilead to continue tallying huge revenues with Harvoni/Sovaldi despite discounting an estimated 46% from list prices.